Climycin
- Brand:Square Pharmaceuticals Ltd.
- Product Code: Climycin 300 mg
- Availability: In Stock
-
16.00Tk.
Composition
- 150 mg capsule: Each capsule contains Clindamycin Hydrochloride BP
equivalent to Clindamycin 150 mg.
- 300 mg Capsule: Each capsule contains Clindamycin Hydrochloride BP
equivalent to Clindamycin 300 mg.
- Powder for oral
solution: Each 5 ml solution contains
Clindamycin Palmitate Hydrochloride USP equivalent to Clindamycin 75 mg.
- 300 mg Injection: Each 2 ml Clindacin Sterile Solution contains
Clindamycin Phosphate BP equivalent to Clindamycin 300 mg.
- 600 mg Injection: Each 4 ml Clindacin Sterile Solution contains
Clindamycin Phosphate BP equivalent to Clindamycin 600 mg.
Indications
Clindamycin has been
shown to be effective in the treatment of the following infections when caused
by susceptible anaerobic bacteria or susceptible strains of gram positive
bacteria such as Streptococci, Staphylococci and Pneumococci; Upper respiratory
infections, Lower respiratory infections, Skin and soft tissue infections, Bone
and joint infections, Pelvic infections, Intra-abdominal infections, Septicemia
and endocarditis, Dental infections. As an alternative therapy when used in
combination with quinine or amodiaquine for the treatment of multi-drug
resistant Plasmodium falciporum infection.
Description
Clindamycin is a
lincosamide antibiotic used in the treatment of infections caused by
susceptible microorganisms. Clindamycin is a semisynthetic antibiotic derived
from lincomycin.
Aerobic gram-positive
cocci, including: Staphylococcus
aureus, Staphylococcus epidermidis (penicillinase and non-penicillinase
producing strains), Streptococci, Pneumococci.
Anaerobic
gram-negative bacilli, including: Bacteroides species, Fusobacterium species.
Anaerobic
gram-positive non-spore forming bacilli, including: Propionibacterium species, Eubacterium
species, Actinomyces species.
Anaerobic and
microaerophilic gram-positive cocci, including: Peptococcus species, Peptostreptococcus
species, Microaerophilic streptococci, C. perferinges
Dosage & Administration
Dosage
of Clindamycin Capsule:
- Serious Infections: 150 mg-300
mg every six hours.
- More severe infections: 300
mg-450 mg every six hours.
To avoid the
possibility of oesophageal irritation, Clindacin capsules should be taken with
a full glass of water.
Several researches has found that Clindamycin 300 mg capsule provides plasma
concentration over MIC90 for more than 12 hours. This finding
supports the twice-daily dosing of Clindacin 300 mg capsule, particularly in
SSTIs & RTIs. However, in case of bone & joint infections, diabetic
foot infections dose of Clindamycin should be 300 mg capsule 3-4 times daily.
Dosage of Clindamycin
Powder for oral solution:
- Serious infections: 8-12
mg/kg/day divided into 3 or 4 equal doses.
- Severe infections: 13-16
mg/kg/day divided into 3 or 4 equal doses.
- More severe infections: 17-25
mg/kg/day divided into 3 or 4 equal doses.
In pediatric patients
weighing 10 kg or less, 1/2 teaspoon (37.5 mg) three times a day should be
considered the minimum recommended dose.
Dosage of Clindamycin
IV/IM Injection:
Adults-
- Serious infections due to
aerobic gram-positive cocci and the more susceptible anaerobes: 600-1200
mg/day in 2- 4 equal doses.
- More severe infections:
1200-2700 mg/day in 2-4 equal doses.
- For more serious infections:
these doses may have to be increased. In life-threatening situations due
to either aerobes or anaerobes, these doses may be increased.
- Doses of as much as 4800 mg daily
have been given intravenously to adults. Single intramuscular injections
of greater than 600 mg are not recommended.
Neonates (less than 1
month): 15 to 20 mg/kg/day in 3 to 4 equal doses. The lower effective dosage
may be adequate for small prematures.
Pediatric patients (1 month of age to 16 years):
- 20 to 40 mg/kg/day in 3 or 4
equal doses. The higher doses would be used for more severe infections.
- Parenteral therapy may be
changed to Capsules (clindamycin hydrochloride) when the condition
warrants and at the discretion of the physician.
- In cases of (3-hemolytic
streptococcal infections, treatment should be continued for at least 10
days.
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
Clindamycin enhances
the action of other neuromuscular blocking agents. Therefore, it should be used
with caution in patients receiving such agents. Antagonism has been
demonstrated between clindamycin and erythromycin in vitro. Because of possible
clinical significance, these two drugs should not be administered concurrently.
Contraindications
Clindamycin is
contraindicated in patients previously found to be sensitive to clindamycin or
any of the ingredients of this medicine.
Side Effects
The adverse effects
have been reported with the use of clindamycin are- abdominal pain,
oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus,
skin rashes, urticaria.
Pregnancy & Lactation
Pregnancy Category B.
Clindamycin crosses the placenta in humans. After multiple doses, amniotic
fluid concentrations were approximately 30% of maternal concentrations.
Clindamycin should be used in pregnancy only if clearly needed. Clindamycin has
been reported to appear in breast milk. Therefore, it is not recommended for
nursing mothers if not clearly needed.
Precautions & Warnings
Clindamycin should be
prescribed with caution in individuals with a history of gastrointestinal
disease, particularly colitis.
Use in Special Populations
Use in newborns and
infants: When Clindamycin is
administered to newborns and infants (birth to 16 years), appropriate
monitoring of organ system functions is desirable.
Geriatric use: Dose adjustment of Clindamycin is not
necessary.
Overdose Effects
Overdosage with orally
administered clindamycin has been rare. Adverse reactions similar to those seen
with normal doses can be expected, however, unexpected reactions could occur.
Haemodialysis and peritoneal dialysis are not effective in removing clindamycin
from the serum. Overdosage should be treated with simple gastric lavage. No
specific antidote is known.
Therapeutic Class
Macrolides
Reconstitution
Direction
for reconstitution (powder for oral solution): Shake the bottle well to loosen the powder. Add 80 ml of
boiled and cooled water to the dry mixture in the bottle. For ease of
preparation, add water to the bottle in two proportions. Shake well after each
addition until all the powder is in solution. Keep the bottle tightly closed.
The reconstituted solution should be used within 2 weeks if kept at room
temperature.
Dilution of
Clindamycin injection for intravenous use: Clindamycin phosphate must be diluted prior to IV
administration. The concentration of clindamycin in diluent for infusion should
not exceed 18 mg per ml. Infusion rates should not exceed 30 mg per minute.
- Administration of more than
1200 mg in a single 1 hour infusion is not recommended.
- Single IM injections of greater
than 600 mg are not recommended. Dilution is not required for
intramuscular administration.
- Parenteral drug products should
be inspected visually for particulate matter and discoloration prior to
administration, whenever solution and container permit.
Dilution
and Compatibility: Physical and
biological compatibility studies monitored for 24 hours at room temperature
have demonstrated no inactivation or incompatibility with the use of
Clindamycin phosphate Sterile Solution (clindamycin phosphate) in IV solutions
containing sodium chloride, glucose, calcium or potassium, and solutions
containing vitamin B complex in concentrations usually used clinically. No
incompatibility has been demonstrated with the antibiotics cephalothin,
kanamycin, gentamicin, penicillin or carbenicillin.
Physico-Chemical Stability of diluted solutions of Clindacin Injection-
- Room temperature: 16 days at
25°C.
- Refrigeration: 32 days at 4°C.
Storage Conditions
Keep below 30°C
temperature, away from light & moisture. Keep out of the reach of children.
Tags: Climycin